DS8201a in HER2+ Patients Previously Treated with Trastuzumab and a Taxane
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

DS8201a in HER2+ Patients Previously Treated with Trastuzumab and a Taxane

Sponsor: Daiichi Sankyo, Inc.

Protocol DS8201-A-U302: A Phase 3 Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, an Anti-Her2-Antibody Drug Conjugate, Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane.